Back to Journals » OncoTargets and Therapy » Volume 10

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

Authors Yao JC, Chan JA, Mita AC, Kundu MG, Hermosillo Reséndiz K, Hu K, Ravichandran S, Strosberg JR, Wolin EM

Received 23 November 2016

Accepted for publication 29 March 2017

Published 27 June 2017 Volume 2017:10 Pages 3177—3186


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 4

Editor who approved publication: Dr XuYu Yang

James C Yao,1 Jennifer A Chan,2 Alain C Mita,3 Madan G Kundu,4 Karina Hermosillo Reséndiz,4 Ke Hu,4 Shoba Ravichandran,4 Jonathan R Strosberg,5 Edward M Wolin6

1GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2Gastrointestinal Cancer Center, Dana–Farber Cancer Institute, Boston, MA, 3Experimental Therapeutics, Cedars-Sinai Medical Center, Los Angeles, CA, 4Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 6Oncology, Montefiore Einstein Center for Cancer Care, Bronx, NY, USA

Abstract: This phase I study aimed at determining the maximum tolerated dose (MTD) and characterizing the safety, tolerability, pharmacokinetics (PKs), and efficacy of pasireotide in patients with advanced neuroendocrine tumors (NETs). Patients were enrolled in two phases: dose-escalation phase (to determine the MTD) at a starting dose of 80 mg pasireotide long-acting release (LAR) i.m. followed by a dose-expansion phase (to evaluate safety and preliminary efficacy). Associations between PK/pharmacodynamic parameters and clinical outcomes were evaluated using linear regression analysis. A total of 29 patients were treated with 80 mg (n=13) and 120 mg (n=16) doses. Most common primary tumor sites included small intestine (44.8%), pancreas (24.1%), and lung (17.2%). No protocol-defined dose-limiting toxicities were observed in the study; however, in post hoc analysis, a higher incidence of bradycardia (heart rate [HR] <40 beats per minute [bpm]) was observed with 120 mg (31.3%) vs 80 mg (0%). Two partial responses (PRs) were observed, both in the 120 mg dose cohort. Pasireotide concentrations correlated with tumor shrinkage, although the association was not statistically significant (P=0.08). Among the biomarkers analyzed, insulin-like growth factor 1 (IGF-1) showed a decreasing trend with increasing pasireotide concentration, while chromogranin A (CgA) and neuron-specific enolase (NSE) levels did not show any dose–response relationship. The most common adverse events in any dose group were hyperglycemia, fatigue, and nausea. MTD was defined at 120 mg for pasireotide LAR in patients with advanced NETs. Although objective radiographic responses were rarely observed with somatostatin analogs, two PRs were observed among 16 patients in the 120 mg cohort. Bradycardia (HR <40 bpm) appears to be a dose-limiting effect; however, the mechanism and clinical significance are uncertain. This study was registered with (NCT01364415).

Keywords: pharmacokinetics, pharmacodynamics, MTD, Bayesian logistic regression model, dose escalation with overdose control

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]